Important notification
06.06.2024 To the attention of all Marketing Authorisation Holders / Legal representatives of Marketing Authorisation Holders Please be advised that, […]
Important notification
27.05.2024 To the attention of interested persons The Commission Implementation Decision of 24.05.2024 concerning, within the framework of Article 31 […]
Important notification
20.05.2024 To the attention of applicants and Marketing Authorisation Holders of medicinal products for human use Following the publication of […]
Press release
16.05.2024 To the attention of interested persons Hydroxyprogesterone caproate medicines to be suspended from the EU market. Medicinal products containing […]
Important notification
22.04.2024 To the attention of interested persons List of training providers of medical device legislation, approved by the NAMMDR In […]
Important notification
18.04.2024 To the attention of interested persons The NAMMDR would like to inform you about the 11th Romanian Pharmacovigilance Workshop […]
Important notification
15.04.2024 To the attention of all stakeholders (healthcare units, importers/distributors, patients) As of April 2024, a new SAFETY NOTICES section […]
Press release
12.04.2024 To the attention of interested persons Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8-11 April 2024: GLP-1 […]
Important notification
09.04.2024 To the attention of interested persons Notification regarding professional training and instruction courses for staff with specific duties of […]
Press release
22.03.2024 To the attention of interested persons Synapse Labs Pvt. Ltd: re-examination confirms suspension of medicines over flawed studies download […]